Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for ROS1+ cancer patients: expanded access to zidesamtinib

NCT ID NCT06797362

AVAILABLE Disease control Sponsor: Nuvalent Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program provides the investigational drug zidesamtinib (NVL-520) to adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have no satisfactory treatment options and cannot join a clinical trial. Participants must have received at least one prior ROS1-targeted therapy. The goal is to offer a potential treatment when no alternatives exist.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zidesamtinib (NVL-520), an oral tablet
What this could lead to
If it works, this could provide a treatment option for people with advanced ROS1-positive cancers who have run out of standard therapies.
What could go wrong
This is an expanded access program, not a formal trial, so effectiveness and safety are not fully established. It may not work for everyone and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

  • AUSL della Romagna - Ravenna

    AVAILABLE

    Ravenna, 48121, Italy

  • Antoni van Leeuwenhoek Hospital

    AVAILABLE

    Amsterdam, 1006 BE, Netherlands

  • CHU de Nantes

    AVAILABLE

    Nantes, Pays de la Loire Region, 44800, France

  • Centre Leon Berard

    AVAILABLE

    Lyon, Auvergne-Rhône-Alpes, 69008, France

  • Chris O'Brien Lifehouse

    AVAILABLE

    Camperdown, New South Wales, 2050, Australia

  • Chung Shan Medical University

    AVAILABLE

    Taichung, 402306, Taiwan

  • Cross Cancer Institute

    AVAILABLE

    Edmonton, Alberta, T6G 1Z2, Canada

  • Dana-Farber Cancer Institute

    AVAILABLE

    Boston, Massachusetts, 02215, United States

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    AVAILABLE

    Milan, 20133, Italy

  • Fox Chase Cancer Center

    AVAILABLE

    Philadelphia, Pennsylvania, 19111, United States

  • GCS IUCT Oncopole

    AVAILABLE

    Toulouse, Occitanie, 31059, France

  • Gregorio Marañón General University Hospital

    AVAILABLE

    Madrid, 28007, Spain

  • Hospital Univ Doce de Octubre

    AVAILABLE

    Madrid, 28041, Spain

  • Hospital Universitario Vall d'Hebron

    AVAILABLE

    Barcelona, 08035, Spain

  • IRCCS Istituto Oncologico Veneto

    AVAILABLE

    Padova, 35128, Italy

  • IRCCS Istituto Tumori Giovanni Paolo II

    AVAILABLE

    Bari, 70124, Italy

  • Institut Gustave Roussy

    AVAILABLE

    Villejuif, Île-de-France Region, 94800, France

  • Istituto Nazionale Tumori "Regina Elena

    AVAILABLE

    Roma, 00144, Italy

  • L'Istituto Europeo di Oncologia S.r.l.

    AVAILABLE

    Milan, 20141, Italy

  • Massachusetts General Hospital

    AVAILABLE

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    AVAILABLE

    Manhattan, New York, 10065, United States

  • National Cancer Centre Singapore

    AVAILABLE

    Singapore, 168583, Singapore

  • National Cheng Kung University Hospital

    AVAILABLE

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital

    AVAILABLE

    Taipei, 100229, Taiwan

  • National University Hospital Singapore

    AVAILABLE

    Singapore, 119074, Singapore

  • Netherlands Cancer Institute: NKI

    AVAILABLE

    Amsterdam, 1066 CX, Netherlands

  • Peter MacCallum Cancer Centre

    AVAILABLE

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Hospital

    AVAILABLE

    Toronto, Ontario, M5G 2M9, Canada

  • The Christie Hospital

    AVAILABLE

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden Hospital

    AVAILABLE

    Sutton, Surrey, SM2 5PT, United Kingdom

  • The Royal Marsden Hospital

    AVAILABLE

    London, SM2 5PT, United Kingdom

  • UZLeuven

    AVAILABLE

    Leuven, 3000, Belgium

  • University Medical Center Groningen

    AVAILABLE

    Groningen, 9713 GZ, Netherlands

  • University of Chicago Medical Center

    AVAILABLE

    Chicago, Illinois, 60637, United States

  • University of Colorado Anschutz School of Medicine

    AVAILABLE

    Aurora, Colorado, 80045, United States

  • University of Washington / Fred Hutchinson Cancer Center

    AVAILABLE

    Seattle, Washington, 98109, United States

  • Uomi Cancer Center-Clinica Tres Torres

    AVAILABLE

    Barcelona, 08017, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.